Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
239 Cards in this Set
- Front
- Back
|
Acebutolol
|
β1 partial agonist
|
|
|
Acetylcholine
|
Endogenous AChR agonist
|
|
|
Adrenaline
|
Endogenous α2/β2 agonist
|
|
|
Aspirin
|
NSAID, Irreversible COX1-3 inhibitor
|
|
|
Atropine
|
mAChR antagonist, Competitive
|
|
|
Benzilylcholine mustard
|
AChR antagonist Irreversible
|
|
|
α-bungarotoxin
|
NMJ nAChR antagonist, Irreversible
|
|
|
Buprenorphine
|
μ partial agonist, Orally active
|
|
|
Cimetidine
|
H2 antagonist, Peptic ulcer treatment
|
|
|
Cyanopindolol
|
β1 antagonist, Commonly 125I radiolabelled
|
|
|
Fexofenadine
|
H1 antagonist, Does not penetrate BBB
|
|
|
Imatinib
|
Bcr-Abl inhibitor, Treatment of CML
|
|
|
Heroin
|
μ agonist, Acetylated form of morhpine, crosses BBB more readily
|
|
|
Isoprenaline
|
β agonist
|
|
|
Mecamylamine
|
Neuronal nAChR antagonist
|
|
|
Misoprostol
|
EP3 agonist, Synthetic prostaglandin EP1 analogue, peptic ulcer treatment
|
|
|
Morphine
|
μ agonist
|
|
|
Naloxone
|
μ antagonist, Treatment of opioid overdose
|
|
|
Nicotine
|
nAChR agonist
|
|
|
Noradrenaline
|
Endogenous α1/β1 agonist
|
|
|
Omeprazole
|
Gastic parietal cell proton pump inhibitor, Peptic ulcer treatment
|
|
|
Paracetamol
|
NSAID, COX1-3 inhibitor
|
|
|
Pilocarpine
|
mAChR agonist
|
|
|
Prazosin
|
α1 antagonist
|
|
|
Propanolol
|
β antagonist
|
|
|
Pyrilamine
|
H1 antagonist, Penetrates BBB
|
|
|
Terfenadine
|
H1 antagonist, Prodrug, does not penetrate BBB
|
|
|
Yohimbine
|
α2 antagonist
|
|
|
Metformin
|
Mimics insulin effects
|
|
|
Sulphonylureas
|
K+ATP channel inhibitor, Promotes insulin release by depolarising β cells, allowing Ca2+ influx which causes exocytosis
|
|
|
Meglitinide
|
K+ATP channel inhibitor, Promotes insulin release by depolarising β cells, allowing Ca2+ influx which causes exocytosis (lower affinity than sulphonylureas)
|
|
|
Thiazolidinedione
|
PPAR agonist, Activates TFs which promote FA storage and glucose metabolism
|
|
|
Acarbose
|
α-glucosidase inhibitor, Reduces glucose intake from GIT
|
|
|
BoNT-A
|
Neurotoxin, Cleaves SNAP-25
|
|
|
BoNT-B
|
Neurotoxin, Cleaves synaptobrevin
|
|
|
BoNT-C
|
Neurotoxin, Cleaves SNAP-25 and syntaxin
|
|
|
BoNT-D
|
Neurotoxin, Cleaves synpatobrevin
|
|
|
BoNT-E
|
Neurotoxin, Cleaves SNAP-25
|
|
|
BoNT-F
|
Neurotoxin, Cleaves synaptobrevin
|
|
|
BoNT-G
|
Neurotoxin, Cleaves synaptobrevin
|
|
|
TeNT
|
Neurotoxin, Cleaves synaptobrevin
|
|
|
Hemicholium
|
ChT inhibitor
|
|
|
Triethylcholine
|
CAT competitive substrate
|
|
|
Vesamicol
|
VAChT inhibitor
|
|
|
β-bungarogtoxin
|
PLA2 activity, In cholinergic nerves
|
|
|
Taipoxin
|
PLA2 activity, In cholinergic nerves
|
|
|
α-latrotoxin
|
Forms Ca2+ permeable channels, In cholinergic nerves
|
|
|
Trimetaphan
|
Ganglionic nAChR antagonist, Competitive
|
|
|
Hexamethonium
|
Ganglionic nAChR antagonist
|
|
|
Decamethonium
|
NMJ nAChR antagonist
|
|
|
d-tubocurarine
|
nAChR antagonist
|
|
|
Pancuronium
|
Non-depolarising NMJ blocker
|
|
|
Rocuronium
|
Non-depolarising NMJ blocker
|
|
|
Atracurium
|
Non-depolarising NMJ blocker
|
|
|
Mivacurium
|
Non-depolarising NMJ blocker
|
|
|
Sugammadex
|
Non-depolaring blockade reversal, Binds steroidal non-depolarising blockers
|
|
|
Suxamethonium
|
Depolarising NMJ blocker
|
|
|
Carbachol
|
AChR agonist
|
|
|
Methacholine
|
mAChR agonist
|
|
|
Cevimeline
|
M3 agonist
|
|
|
Tropicamide
|
mAChR antagonist, Short acting
|
|
|
Ipratopium
|
mAChR antagonist
|
|
|
Pirenzepine
|
M1 antagonist
|
|
|
Darifenicin
|
M3 antagonist
|
|
|
Edrophonium
|
AChE Inhibitor, Short acting
|
|
|
Tacrine
|
AChE Inhibitor, Short acting
|
|
|
Donezepil
|
AChE Inhibitor, Short acting
|
|
|
Neostigmine
|
AChE Inhibitor, Medium acting
|
|
|
Pyridostigmine
|
AChE Inhibitor, Medium acting
|
|
|
Rivastigmine
|
AChE Inhibitor, Medium acting
|
|
|
Dyflos
|
AChE Inhibitor, Long acting
|
|
|
Ecothiapate
|
AChE Inhibitor, Long acting
|
|
|
Malathion
|
AChE Inhibitor, Long acting
|
|
|
Pralidoxime
|
AChE reactivator
|
|
|
a-methyltyrosine
|
Tyrosine hydroxylase inhibitor, Competitive
|
|
|
L-DOPA
|
DOPA decarboxylase substrate
|
|
|
Carbidopa
|
DOPA decarboxylase inhibitor
|
|
|
Benserazide
|
DOPA decarboxylase inhibitor
|
|
|
Droxidopa
|
NA precursor
|
|
|
Disulfiram
|
Dopamine β hydroxylase inhibitor
|
|
|
Methyldopa
|
False transmitter precursor
|
|
|
6-hydroxydopamine
|
Neurotoxin, Kills noradrenergic nerves
|
|
|
Reserpine
|
VMAT inhibitor
|
|
|
Ephedrine
|
Sympathomimetic monoamine, Indirect
|
|
|
Dextroamphetamine
|
Sympathomimetic monoamine, Indirect
|
|
|
Guanethidine
|
NA release inibitor
|
|
|
Desiprimine
|
NET inhibitor
|
|
|
Amitriptyline
|
NET/SERT inhibitor
|
|
|
Fluoxetine
|
SSRI
|
|
|
Citalopram
|
SSRI
|
|
|
Cocaine
|
NET/SERT/DAT inhibitor
|
|
|
Phenoxybenzamine
|
Irreversible α1/α2 antagonist
|
|
|
Moclobemide
|
MAO-A inhibitor
|
|
|
Selegiline
|
MAO-B inhibitor
|
|
|
Entacapone
|
COMT inhibitor
|
|
|
Phenylephrine
|
α1/α2 agonist
|
|
|
Methoxamine
|
α1/α2 agonist
|
|
|
Clonidine
|
α2 agonist, Relatively selective, also activates I receptors
|
|
|
Xylazine
|
α2 agonist, Relatively selective
|
|
|
Dexmedetomidine
|
α2 agonist, Relatively selective
|
|
|
Dobutamine
|
β1 agonist
|
|
|
Salbutamol
|
β2 agonist, Short acting
|
|
|
Salmeterol
|
β2 agonist, Long acting
|
|
|
Formoterol
|
β2 agonist, Long acting
|
|
|
Indacaterol
|
β2 agonist, Ultra long lasting
|
|
|
Mirabegron
|
β3 agonist
|
|
|
Labetalol
|
α/β antagonist
|
|
|
Phentolamine
|
α1/α2 antagonist
|
|
|
Doxazosin
|
α1 antagonist
|
|
|
Tamsulosin
|
α1A antagonist
|
|
|
Propranolol
|
β1/β2 antagonist
|
|
|
Atenolol
|
β1 antagonist
|
|
|
Nebivolol
|
β1 antagonist, Metabolite is β3 agonist
|
|
|
Caffeine
|
A1 antagonist
|
|
|
Dipyramidole
|
NsT inhibitor
|
|
|
Desmopressin
|
ADH synthetic analogue
|
|
|
Glyceryl trinitrate
|
NO donor
|
|
|
Sildenafil
|
PDE V inhibitor
|
|
|
Alprostadil
|
PGE1 analogue
|
|
|
Amyl nitrite
|
NO donor
|
|
|
L-NAME
|
NOS inhibitor, Non-selective
|
|
|
7-NI
|
Neuronal NOS inhibitor
|
|
|
L-NIO
|
iNOS inhibitor, Irreversible
|
|
|
Bacitracin
|
Peptidoglycan synthesis inhibitor, Inhibits dephosphorylation of bactoprenol pyrophosphate carrier
|
|
|
D-cycloserine
|
Peptidoglycan synthesis inhibitor, D-Ala analogue, L-Ala racemase/D-Ala-D-Ala synthetase/D-Ala-D-Ala muramyl tripeptide ligase inhibitor
|
|
|
Fosfomycin
|
Peptidoglycan synthesis inhibitor, Pyruvyl transferase inhibitor
|
|
|
Isoniazid
|
Mycolic acid synthesis inhibitor, First line TB treatment
|
|
|
Penicillin
|
Peptidoglycan synthesis inhibitor, β-lactam antibiotic
|
|
|
Ampicillin
|
Peptidoglycan synthesis inhibitor, β-lactam antibiotic
|
|
|
Amoxicillin
|
Peptidoglycan synthesis inhibitor, β-lactam antibiotic
|
|
|
Methicillin
|
Peptidoglycan synthesis inhibitor, β-lactam antibiotic
|
|
|
Clavulanate
|
β-lactamase inhibitor
|
|
|
Augmentin
|
Amoxicillin/Clavulanate combination therapy
|
|
|
Vancomycin
|
Peptidoglycan synthesis inhibitor, Prevents D-Ala-D-Ala cross-linking
|
|
|
Chloramphenicol
|
Protein synthesis inhibitor, Prevents aminoacyl tRNA binding to 50s subunit
|
|
|
Erythromycin
|
Protein synthesis inhibitor, Macrolide, blocks polypeptide exit tunnel
|
|
|
Fusidic acid
|
Protein synthesis inhibitor, Binds EF-G, preventing movement of 30s subunit
|
|
|
Streptomycin
|
Protein synthesis inhibitor, Aminoglycoside, targets 30s subunit and decreases translation fidelity
|
|
|
Gentamycin
|
Protein synthesis inhibitor, Aminoglycoside, targets 30s subunit and decreases translation fidelity
|
|
|
Tetracycline
|
Protein synthesis inhibitor, Binds 30s subunit and inhibits movement of aminoacyl tRNA into A site
|
|
|
Bleomycin
|
Nucleic acid antibiotic, Metal-chelating, generates ROS to cause single and double strand breaks
|
|
|
Ciprofloxacin
|
DNA gyrase inhibitor, Fluoroquinolone, cause DNA supercoiling
|
|
|
Daunomycin
|
Cytotoxic drug, Intercalates dsDNA and causes local unwinding
|
|
|
Mitomycin C
|
Nucleic acid antibiotic, Alkylates and cross-links DNA
|
|
|
Rifampin
|
RNA polymerase inhibitor
|
|
|
Sulfamethoxazole
|
Antimetabolite antibiotic, Competitively inhibits dihydropterate synthase in tetrahydrofolate synthesis
|
|
|
Trimethoprim
|
Antimetabolite antibiotic, Inhibits dihydrofolate reductase in tetrahydrofolate synthesis
|
|
|
Co-trimoxazole
|
Sulfamethoxazole/Trimethoprim combination therapy
|
|
|
Amphotericin B
|
Membrane antibiotic, Targets ergosterol in fungal and parasitic membranes, pore-forming
|
|
|
Flucanazole
|
Membrane antibiotic, Inhibits ergosterol synthesis
|
|
|
Miconazole
|
Membrane antibiotic, Inhibits ergosterol synthesis
|
|
|
Gramicidin A
|
Membrane antibiotic, Ion channel forming
|
|
|
Polymixin
|
Membrane antibiotic, Cationic detergent, alters membrane permeability
|
|
|
Valinomycin
|
Membrane antibiotic, K+ transmembrane shuttle
|
|
|
Artemisinin
|
Antiparasitic, Produces ROS in RBC stage
|
|
|
Chloroquine
|
Antiparasitic, Inhibits haem polymerisation, toxic to plasmodium
|
|
|
Mefloquine
|
Antiparasitic, Inhibits haem polymerisation, toxic to plasmodium
|
|
|
Clorsulon
|
Antiparasitic, Phosphoglycerate kinase/mutase inhibitor
|
|
|
Closantel
|
Antiparasitic, Oxidative phosphorylation uncoupler
|
|
|
Diclorvos
|
Antiparasitic, Cholinesterase inhibitor, spastic paralysis
|
|
|
Ivermectin
|
Antiparasitic, Opens chloride channels, hyperpolarisation
|
|
|
Levamisole
|
Antiparasitic, Nicotinic agonist, spastic paralysis
|
|
|
Melarsen
|
Antiparasitic, Arsenic compound, selectively accumulated
|
|
|
Paraherquamide
|
Antiparasitic, Nicotinic antagonist, flaccid paralysis
|
|
|
Praziquantel
|
Antiparasitic, Increase Ca2+ permeability
|
|
|
Pyrimethamine
|
Antiparasitic, Dihydrofolate reductase inhibitor (trimethoprim analogue)
|
|
|
Sulfadoxin
|
Antiparasitic, Dihydropterate synthase inhibitor (sulfamethoxazole analogue)
|
|
|
Suramin
|
Antiparasitic (mechanism unknown), P2X antagonist
|
|
|
Thiobenzdole
|
Antiparasitic, Enhances tubulin depolymerisation
|
|
|
Acyclovir
|
Antiviral, Activated by viral thymidine kinase, inhibits viral DNA polymerase
|
|
|
Amantadine
|
Antiviral, M2 channel antagonist, prevents influenza acidification
|
|
|
Gancyclovir
|
Antiviral, Activated by viral thymidine kinase, inhibits viral DNA polymerase
|
|
|
Cidofovir
|
Antiviral, Cytosine analogue, inhibits viral DNA polymerase
|
|
|
Foscarnet
|
Antiviral, Pyrophosphate analogue, inhibits viral DNA polymerase
|
|
|
Interferon
|
Antiviral, Immunoregulatory cytokine
|
|
|
Nevirapine
|
Antiviral, HIV non-nucleoside RT inhibitor
|
|
|
Oseltamivir
|
Antiviral, Neuraminidase inhibitor
|
|
|
Zanamivir
|
Antiviral, Neuraminidase inhibitor
|
|
|
Saquinavir
|
Antiviral, HIV protease inhibitor
|
|
|
Zidovudine
|
Antiviral, Thymidine analogue, RT inhibitor
|
|
|
AZT
|
Antiviral, Thymidine analogue, RT inhibitor
|
|
|
HAART
|
Nevirapine/Zidovudine/Saquinavir combination therapy
|
|
|
5-Fluorouracil
|
Anticancer, Antimetabolite, thymidylate synthase inhibitor
|
|
|
Cyclophosphamide
|
Anticancer, Alkylating agent
|
|
|
Lomustine
|
Anticancer, Alkylating agent, lipid soluble
|
|
|
Carmustine
|
Anticancer, Alkylating agent, lipid soluble
|
|
|
Dactinomycin
|
Anticancer, Intercalating agent
|
|
|
Doxorubicin
|
Anticancer, Causes oxidative DNA damage
|
|
|
Taxol
|
Anticancer, Stabilises mitotic spindle
|
|
|
Colchicine
|
Anticancer, Prevents tubulin assembly
|
|
|
Tamoxifen
|
Anticancer, ERα antagonist
|
|
|
Herceptin
|
Anticancer, Her2 antagonist
|
|
|
Ipilimumab
|
Anticancer, Targets CTLA-4
|
|
|
Parp inhibitors
|
Anticancer, Synthetic lethality
|
|
|
Lidocaine
|
Local anaesthetic, Class IB antidysrhythmic, vNa antagonist
|
|
|
Lamotrigine
|
Local anaesthetic, vNa antagonist
|
|
|
Tetrodotoxin
|
Neurotoxin, vNa antagonist
|
|
|
Phenytoin
|
Anticonvulsant, vNa antagonist
|
|
|
Kainate
|
AMPA agonist
|
|
|
Alteplase
|
Plasminogen activator
|
|
|
Desmoteplase
|
Plasminogen activator
|
|
|
Topiramate
|
Anticonvulsant
|
|
|
Valproate
|
Anticonvulsant
|
|
|
Batrachotoxin
|
vNa agonist, Prevents inactivation
|
|
|
α-scorpion toxin
|
vNa agonist, Prevents inactivation
|
|
|
Verapamil
|
Phenylalkylamine, class IV antidysrhythmic, L-type Ca2+ channel antagonist
|
|
|
Nifedipine
|
Dihydropyridine, L-type Ca2+ channel antagonist
|
|
|
BAY K 8664
|
Dihydropyridine, L-type Ca2+ channel agonist
|
|
|
Diltiazem
|
Benzothiazepine, L-type Ca2+ channel antagonist
|
|
|
Quinidine
|
Class IA antidysrhythmic
|
|
|
Flecainide
|
Class IC antidysrhythmic
|
|
|
Amiodarone
|
Class III antidysrhythmic, Mechanism unknown, prolongs AP
|
|
|
Digoxin
|
Na+/K+-ATPase inhibitor, Cardiac glycoside
|
|
|
Digitoxin
|
Na+/K+-ATPase inhibitor, Cardiac glycoside
|
|
|
Oubain
|
Na+/K+-ATPase inhibitor, Cardiac glycoside
|
|
|
Theophylline
|
PDE inhibitor
|
|
|
Milrinone
|
PDE inhibitor
|
|
|
Mannitol
|
Osmotic diuretic, Increases tubular osmotic pressure
|
|
|
Acetazolamide
|
Carbonic anhydrase inhibitor
|
|
|
Furosemide
|
Loop diuretic, Inhibits NKCC
|
|
|
Bendroflumethiazide
|
Thiazide diuretic, Inhibits Na+/Cl- antiporter
|
|
|
Hydrochlorothiazide
|
Thiazide diuretic, Inhibits Na+/Cl- antiporter
|
|
|
Spironolactone
|
AT1R antagonist
|
|
|
Amiloride
|
ENAC blocker
|
|
|
Glycyrrhetinic acid
|
11β-HSD inhibitor
|
|
|
Catopril
|
ACE inhibitor
|
|
|
Enalapril
|
ACE inhibitor
|
|
|
Losartan
|
AT1R antagonist
|
|
|
Valsartan
|
AT1R antagonist
|
|
|
Simvastatin
|
HMG-CoA reductase inhibitor, Reversible
|
|
|
Lovastatin
|
HMG-CoA reductase inhibitor, Reversible
|
|
|
Atorvastatin
|
HMG-CoA reductase inhibitor, Long acting
|
|
|
Bezafibrate
|
PPARα agonist, Reduce VLDL and LDL levels
|
|
|
Ciprofibrate
|
PPARα agonist, Reduce VLDL and LDL levels
|
|
|
Clofibrate
|
PPARα agonist, Reduce VLDL and LDL levels
|
|
|
Ezaetimibe
|
NPC1L1 blocker, Reduces cholesterol absorption
|
|
|
Isosorbide mononitrate
|
NO donor
|
|
|
Ivabradine
|
HCN blocker, Inhibits If at SAN
|
|
|
Ranolazine
|
vNa antagonist, Reduces late Na+ current in cardiac AP
|
